SPRC

Toronto, ON – July 2, 2026 - TheNewswire – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, further to its press release dated June 30, 2026, it has increased the size of its previously announced non-brokered private placement (the " Offering ") and extended the expiry term of the Unit Warrants (as defined below). The Company now intends to issue up to 45,000,000 units (each, an “ Offered Unit ”) at a price of C$0.12 per Offered Unit for gross proceeds of up to approximately C$5,400,000 under the Offering.     Each Offered Unit will be comprised of one (1) common share in the capital of the Company (each, a “ Unit Share ”) and one (1) transferable common share purchase warrant (each, a “ Unit Warrant ”) entitling the holder thereof to acquire one common share in the capital of the Company (each, a “ Unit Warrant Share ”) at a USD exercise price equivalent to C$0.16 per Unit Warrant Share (to be calculated on the date of closing of the Offering) for a period of 36 months from the date of issuance thereof, an increase to the previously announced 24 month expiry period for the Unit Warrants.  The Unit Warrants will also have an acceleration provision whereby upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, NeuroThera will accelerate the expiry date of 50% of the unexercised Unit Warrants.

TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum").

Toronto, Ontario – June 3, 2026 – TheNewswire –  NeuroThera Labs Inc. (TSXV: NTLX) (the “ Company ” or “ NeuroThera ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed its previously announced acquisition (the “ Transaction ”) of an aggregate of 56,375 ordinary shares (the “ Purchased Shares ”) in the capital of CliniQuantum Ltd. (“ CliniQuantum ”), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum, pursuant to a share purchase agreement dated March 9, 2026, as amended by an amending agreement dated April 30, 2026 (collectively, the “ SPA ”), among the Company, CliniQuantum and the holders of the Purchased Shares (collectively, the “ Selling Shareholders ”). The Transaction was initially announced by news release dated March 10, 2026 and updated by news release dated May 27, 2026.   As consideration for the Purchased Shares, the Company issued an aggregate of 56,600,000 common shares in the capital of the Company (the “ Consideration Shares ”) from treasury to the Selling Shareholders, representing an aggregate deemed value of approximately $9,459,954.20 (the “ Purchase Price ”) based on the 20-day volume weighted average trading price of the Company's common shares (the “ Current Market Price ”) on the TSX Venture Exchange (the “ TSXV ”) as at the date of the SPA. No cash consideration was paid for the Purchased Shares.

SciSparc Ltd. (NASDAQ:SPRC) stock is surging on Thursday.

TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”).

April 30, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC) (“ SciSparc ”), is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario) (the " OBCA "). Shareholders approved the continuance into the OBCA by special resolution at the Company's special meeting of shareholders held on April 10, 2026.   In connection with the continuance, the Company has replaced its notice of articles and articles with new articles of continuance and by-laws, respectively, under the OBCA, which can be accessed at the Company's profile at www.sedarplus.com . The CUSIP / ISIN numbers for the Company's common shares and the stock symbol for the Company's common shares remain unchanged.